The Outcome of Fetal Reduction in High Order Multiple Pregnancy
DOI:
https://doi.org/10.46966/msjar.v7i1.362Keywords:
Fetal Reduction, High Order Multiple PregnancyAbstract
Background: High-order multiple pregnancies, is rising in incidence owing to rising incidence of assisted reproduction -conceived pregnancies, thus, start to emerge as a not infrequently seen challenge in our daily gyn/ob- daily clinical practice. The term of high order multifetal pregnancy is applied to gestation involving three or more fetuses, and is associated with significant maternal and neonatal complications, largely due to increased rates of preterm birth and low birth weight. Multifetal pregnancy reduction has been proposed as a strategy to improve perinatal outcomes, the technique was introduced in our middle Euphrates governorates (including Annajaf AlAshraf) relatively only recently, and its acceptance is still questionable among ART physicians. In this paper we try to show our patients series outcomes for all procedure done in our private center since it was first introduced in 2021 till the time we accomplished this paper. Objective: the aim of the study is to express maternal and neonatal outcomes of all high-order multiple pregnancies underwent multifetal reduction management to twin pregnancies, including our own figure of procedure- related pregnancy loss rate. Methods: This retrospective cohort study included 15 women with triplet or quadruplet pregnancies diagnosed before 10 weeks of gestation and managed at Al –Ameer assisted reproduction center in Annajaf Al-Ashraf province in Iraq managed with fetoreduction at 9-10 weeks of gestation having their pregnancies followed in collaboration with Al-Zahraa Maternity and Children's Teaching Hospital a teaching center affiliated to medical school of Kufa university, from January 2021 to September 2024. Maternal and neonatal outcomes, including gestational age at delivery, perinatal complications, birth weight, Apgar scores, maternal complications, and our own figure of intervention- associated pregnancy loss rate were all assessed in numbers and percentages. Results: of 15 collected sample studied 8 women were of the age group(25.1–30years), all the 15 were in their 1st pregnancy( primigravidae), 13 were with triplets and two of 15 with quadruplets, all of them were already diagnosed and are treated by fetoreduction 9-10 weeks, 11/15(73.3%) delivered at term, 13.3 % delivered at late preterm gestational age(35-36 weeks), 6.6% delivered at very preterm (29 weeks), 6.6% aborted at 18 weeks due to covid infection, there was no perinatal deaths of those reached potential viable pregnancy stage(14/14) with all live births had survived, with their Apgar Scores; 6.70 ± 1.77& 8.00 ± 3.97 at 1&5 minutes respectively, 21.4%(3/14) of reduced pregnancies developed preterm birth with or without prelabour rupture of fetal membranes all survived, our own procedure- related pregnancy loss rate is 0%.Conclusion: Fetoreduction in high-order multiple pregnancies appears to improve neonatal outcomes and reduce maternal complications, particularly preterm delivery and perinatal death. The study shows that fetoreduction is an effective management option in high-order multiple pregnancies even though it leads to more cesarean deliveries. To confirm these findings and improve clinical practices, more prospective studies across multiple centers are needed.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Batool A. Hashim AlKhalidi

This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


















